直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Introduction to Intellectual Property: A U.S. Perspective

March 27, 2015

Cold Spring Harbor Perspectives in Medicine

By Thomas Lee Irving; Amanda K. Murphy, Ph.D.; *Stacy D. Lewis

Many biotechnology innovators opt for patents, which grant legal, time-limited monopolies to eligible inventions. To obtain a patent in the United States, an invention must be useful to the public and made or altered by the hand of man. It must then clear the hurdles of novelty and nonobviousness. If an invention can do that, obtaining a patent becomes a matter of form: Who qualifies as an inventor? Does the application demonstrate possession, stake a clear claim to the protection sought, and enable “ordinary” colleagues to replicate it? Has the inventor purposely withheld anything? In this article, Finnegan attorneys Thomas L. Irving, Amanda K. Murphy, and Michael A. Stramiello address each of these hurdles as they apply to biotech inventions.

*Stacy Lewis is a law clerk at Finnegan.

Tags

patent-eligible, claim construction

Related Practices

Prosecution and Portfolio Management

Trade Secrets

Related Industries

Life Sciences

Biotechnology

Related Offices

Washington, DC

Related Professionals

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Originally printed in Cold Spring Harbor Perspectives in Medicine. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Conference

IAM Live: Navigating the UPC 2026

November 3, 2026

Paris

Conference

2026 AIPLA Annual Meeting

October 29-31, 2026

Washington, DC

Seminar

Future IP UK

October 21, 2026

London

Conference

ChIPs Global Summit 2026

October 21-23, 2026

Los Angeles

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Conference

31st Annual UMass Chan Research Retreat

October 14-15, 2026

Worcester

Hybrid Conference

Intellectual Property Law Institute 2026 – New York

September 28-29, 2026

New York

Conference

2026 IPO Annual Meeting

September 27-29, 2026

Toronto

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP